Last update: Aug. 29, 2021
Minimal risk for breastfeeding and infant.
Indicated in the treatment and prevention of arterial, venous or pulmonary thromboembolism and in acute coronary syndrome.
Authorized use in neonates and infants.
Subcutaneous or intravenous administration.
It is excreted in breast milk in a clinically non-significant amount (Richter 2001, Harenberg 1987).
No problems have been observed in infants of mothers treated with dalteparin (Richter 2001, Lindhoff 2000).
The high molecular weight of standard or unfractionated heparin and also of low molecular weight heparins makes their passage into breast milk in clinically significant amounts highly unlikely.
In addition, heparins are inactivated in the gastrointestinal tract, not being absorbed (practically zero oral bioavailability), which prevents the passage into plasma of the infant from ingested breast milk.
The risk of heparin-induced thrombocytopenia and osteoporosis is lower with low molecular weight heparins (Fuller 2013, Middeldorp 2011, Rath 2010).
The manufacturer, various medical societies, experts, and expert consensus consider the use of this medication safe during breastfeeding (Hale, Lactmed, Bates 2018 and 1997, Noviani 2016, Briggs 2015, Schaefer 2015, Rowe 2013, Fuller 2013, Yurdakök 2012, Rath 2010).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.